The approval of the first immune checkpoint inhibitors provided a paradigm shift for the
treatment of malignancies across a broad range of indications. Whereas initially, single …

Circulating cell-free tumor DNA (ctDNA) can serve as a real-time biomarker of tumor burden
and provide unique insights into the evolving molecular landscape of cancers under the …

Therapeutic vaccines that elicit cytotoxic T cell responses targeting tumor-specific
neoantigens hold promise for providing long-term clinical benefit to patients with cancer …

Purpose: Chemoimmunotherapy (chemoIO) is a prevalent first-line treatment for advanced
driver-negative non–small cell lung cancer (NSCLC), with maintenance therapy given after …

Liquid biopsies using cell-free circulating tumor DNA (ctDNA) are being used frequently in
both research and clinical settings. ctDNA can be used to identify actionable mutations to …

The therapeutic landscape for patients with advanced malignancies has changed
dramatically over the last twenty years. The growing number of targeted therapies and …

In the era of precision oncology, use of circulating tumor DNA (ctDNA) is emerging as a
minimally invasive approach for the diagnosis and management of patients with cancer and …

Purpose: Patients with small-cell lung cancer (SCLC) have an exceptionally poor prognosis,
calling for improved real-time noninvasive biomarkers of therapeutic response. Experimental …

The increasing breadth and depth of resolution in biological and clinical data, including‐
omics and real‐world data, requires advanced analytical techniques like artificial …

Purpose: Although immunotherapy is the mainstay of therapy for advanced non–small cell
lung cancer (NSCLC), robust biomarkers of clinical response are lacking. The heterogeneity …